LegisTrack
Back to all bills
S 724119th CongressIn Committee

Temporary Extension of Fentanyl-Related Substances Scheduling Act

Introduced: Feb 25, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs

This bill, titled the Temporary Extension of Fentanyl-Related Substances Scheduling Act, would extend by six months the temporary scheduling order that covers fentanyl-related substances. Specifically, it would modify Section 2 of the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act (Public Law 116-114) to move the end date from March 31, 2025 to September 30, 2025. The bill was introduced in the Senate by Senator Cory Booker on February 25, 2025, and referred to the Senate Judiciary Committee. In practical terms, the bill preserves the current temporary control over fentanyl analogues for an additional six months, keeping those substances subject to emergency scheduling and the associated penalties and regulatory controls while broader policy decisions or additional study are considered.

Key Points

  • 1Purpose: Extend the temporary scheduling authority for fentanyl-related substances for six months.
  • 2Extension period: End date moved from March 31, 2025 to September 30, 2025.
  • 3Legal basis: Amends Section 2 of the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act (Public Law 116-114).
  • 4Legislative status: Introduced in the Senate; sponsored by Senator Cory Booker; referred to the Judiciary Committee.
  • 5Practical effect: Maintains existing emergency scheduling and related penalties for fentanyl analogues during the extended period, ensuring continued regulatory control and enforcement while further study or policy decisions proceed.

Impact Areas

Primary group/area affected: Law enforcement, prosecutors, and the federal regulatory system (DEA) responsible for implementing and enforcing emergency scheduling of fentanyl-related substances.Secondary group/area affected: Public health agencies and harm-reduction initiatives, which rely on clear regulatory status to address fentanyl-related harms and monitor drug trends.Additional impacts: Drug manufacturers, distributors, and researchers may face ongoing regulatory constraints for fentanyl analogues; state and local governments may experience continued enforcement alignment with federal scheduling decisions; communities impacted by opioid and fentanyl crises may benefit from continued regulatory safeguards and enforcement.
Generated by gpt-5-nano on Nov 18, 2025